secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mural Oncology plc (—)
CIK:        0001971543
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001193125-25-080765
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Mural Oncology ends nemvaleukin alfa development, cuts 90% of staff
-------------------------------------------------------------------

- Discontinues all clinical development of nemvaleukin alfa after phase 2 ARTISTRY-6 and phase 3 ARTISTRY-7 trial data.
- Workforce reduction of approximately 104 positions, or about 90%, expected to complete by end of Q2 2025.
- Estimated costs of $9.0-$10.0 million in severance and benefits, plus $2.0-$4.0 million in non-cash impairment charges.
- Engages Lucid Capital Markets to explore strategic alternatives focused on maximizing shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971543/000119312525080765/0001193125-25-080765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971543/000119312525080765/d940480d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-080765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer